These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36314943)

  • 21. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Polack FP; Thomas SJ; Kitchin N; Absalon J; Gurtman A; Lockhart S; Perez JL; Pérez Marc G; Moreira ED; Zerbini C; Bailey R; Swanson KA; Roychoudhury S; Koury K; Li P; Kalina WV; Cooper D; Frenck RW; Hammitt LL; Türeci Ö; Nell H; Schaefer A; Ünal S; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
    N Engl J Med; 2020 Dec; 383(27):2603-2615. PubMed ID: 33301246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluate the side effect associated with COVID-19 vaccine on adolescents in Riyadh, Saudi Arabia: A cross-section study.
    Aldali JA; Alotaibi FT; Alasiri GA; Almesned RA; Alromih AM; Almohandes AM; Alsenidi SF
    Saudi Med J; 2022 Nov; 43(11):1248-1253. PubMed ID: 36379531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
    Malden DE; Gee J; Glenn S; Li Z; Mercado C; Ogun OA; Kim S; Lewin BJ; Ackerson BK; Jazwa A; Weintraub ES; McNeil MM; Tartof SY
    Vaccine; 2023 Jan; 41(2):315-322. PubMed ID: 36351861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan.
    Miyazaki H; Watanabe D; Ito Y; Okamoto N; Tokunaga E; Ku Y; Ooi M; Hoshi N; Kodama Y
    Dig Dis Sci; 2023 Feb; 68(2):564-570. PubMed ID: 36178566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.
    Hassan YAM; Daud Ali M; Al-Eid RR; Al-Ghuraya FA; Essa Alqasimi Z; Ahmad A; Eltrafi Z; Ghosn SA
    Vaccine; 2022 Nov; 40(49):7087-7096. PubMed ID: 36404426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
    Saita M; Yan Y; Ito K; Sasano H; Seyama K; Naito T
    J Infect Chemother; 2022 Jan; 28(1):116-119. PubMed ID: 34580011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.
    Khan QJ; Bivona CR; Martin GA; Zhang J; Liu B; He J; Li KH; Nelson M; Williamson S; Doolittle GC; Sun W; Mudaranthakam DP; Streeter NR; McGuirk JP; Al-Rajabi R; Hoffmann M; Kasi A; Parikh RA; Zhong C; Mitchell L; Pessetto ZY; Pathak H; Ghosh A; LaFaver S; Sharma P; Godwin AK
    JAMA Oncol; 2022 Jul; 8(7):1053-1058. PubMed ID: 35446353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expectations and Prior Experiences Associated With Adverse Effects of COVID-19 Vaccination.
    Schäfer I; Oltrogge JH; Nestoriuc Y; Warren CV; Brassen S; Blattner M; Lühmann D; Tinnermann A; Scherer M; Büchel C
    JAMA Netw Open; 2023 Mar; 6(3):e234732. PubMed ID: 36972051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of blood groups, vaccine type and gender in predicting the severity of side effects among university students receiving COVID-19 vaccines.
    Almalki OS; Santali EY; Alhothali AA; Ewis AA; Shady A; Fathelrahman AI; Abdelwahab SF
    BMC Infect Dis; 2023 Jun; 23(1):378. PubMed ID: 37280542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.
    Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT
    JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.
    Beatty AL; Peyser ND; Butcher XE; Cocohoba JM; Lin F; Olgin JE; Pletcher MJ; Marcus GM
    JAMA Netw Open; 2021 Dec; 4(12):e2140364. PubMed ID: 34935921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of post-vaccine side effects among COVID-19 immunized community of Southern Pakistan.
    Qureshi A; Syed Sulaiman SA; Rehman W; Mehmood A; Idrees S; Kumar N
    PLoS One; 2023; 18(5):e0285736. PubMed ID: 37220099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.
    Su WJ; Liu YL; Chang CH; Lin YC; Huang WI; Wu LC; Chen SF; Lin YS; Hsieh YL; Yang CA; Lin CH; Chan KA; Lee PI; Chuang JH; Yang CH
    J Microbiol Immunol Infect; 2023 Jun; 56(3):558-565. PubMed ID: 36804307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.
    Kadali RAK; Janagama R; Peruru S; Gajula V; Madathala RR; Chennaiahgari N; Malayala SV
    J Med Virol; 2021 Jul; 93(7):4420-4429. PubMed ID: 33822361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years.
    Toepfner N; von Meißner WCG; Strumann C; Drinka D; Stuppe D; Jorczyk M; Moor J; Püschel J; Liss M; von Poblotzki E; Berner R; Moor MB; Chao CM
    JAMA Netw Open; 2022 Oct; 5(10):e2237140. PubMed ID: 36255723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoking habits predict adverse effects after mRNA COVID-19 vaccine: Empirical evidence from a pilot study.
    Ponticelli D; Losa L; Campagna D; Magliuolo R; Vitale A; Cacciapuoti D; Zampella A; Alleanza L; Schiavone B; Spicuzza L; Ferrara P
    Public Health; 2023 Jun; 219():18-21. PubMed ID: 37086592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons.
    Levi N; Moravsky G; Weitsman T; Amsalem I; Bar-Sheshet Itach S; Algur N; Lapidus I; Mitz O; Glikson M; Wiener-Well Y; Hasin T
    Eur J Heart Fail; 2023 Feb; 25(2):313-318. PubMed ID: 36097844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.